Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

Launched by ASTRAZENECA · Mar 18, 2024

Keywords

ClinConnect Summary

The ORESTES study is a research trial taking place in Spain that aims to understand how patients with Chronic Obstructive Pulmonary Disease (COPD) respond to a medication called Trixeo, which combines three medicines: budesonide, glycopyrronium, and formoterol. The study will look at patients who start using Trixeo and track their health outcomes over a year. Researchers want to learn more about the characteristics of these patients and how effective the treatment is for them in the real world.

To participate in this study, patients need to be at least 40 years old and have a confirmed diagnosis of COPD, which is verified through a specific breathing test. They should have started treatment with Trixeo at least a year before the study begins. However, patients who are using Trixeo for conditions other than COPD or those who are currently involved in another clinical trial cannot take part. If eligible, participants can expect to share their health information for up to 12 months and help researchers gain insights that could improve COPD treatment for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1 .Patient diagnosed with COPD confirmed by spirometry (postbronchodilator FEV1/FVC\<0.7).
• • 2. Patients treated with BGF initiated at least 12 months before start of data collection.
• • 3. Patients with information available at least 12 months before BGF initiation.
• • 4. Adult patients aged ≥40 years old at index date.
• Exclusion Criteria:
• • 1. Subjects with BGF treatment not intended for COPD (e.g., intended for asthma).
• • 2. Subject participated in a clinical trial during the study data observation period.